Allosteric modulation of the M1 muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1185-1199

  Melancon, Bruce J ^a   Tarr, James C ^a   Panarese, Joseph D ^a   Wood, Michael R ^a   Lindsley, Craig W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 42; BRUCINE; CLOZAPINE; G PROTEIN COUPLED RECEPTOR; IFENPRODIL; LY 503430; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANSFERRIN BINDING PROTEIN B; UNCLASSIFIED DRUG; VU 0357017; VU 0364572; VU 0409066; VU 0413144; VU 0415371; VU 0420385; VU 0447360; VU0357017; VU0364572; XANOMELINE; PYRIDINE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ALLOSTERISM; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; COGNITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DRUG DESIGN; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; MUSCARINIC AGONISTS; PYRIDINES; RECEPTOR, MUSCARINIC M1; SCHIZOPHRENIA; THIADIAZOLES;

EID: 84889099313     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.09.005     Document Type: Review

References (94)

1. K. Mueser, and S. McGurk Schizophrenia Lancet 363 2004 2063 2072
2. D.C. Javitt When doors of perception close: bottom-up models of disrupted cognition in schizophrenia Annu. Rev. Clin. Psychol. 5 2009 249 275
3. J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 2005 1 93
4. M. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330
5. R.S. Keefe Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch. Gen. Psychiatry 64 2007 633 647
6. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377
7. C. Ross Neurobiology of schizophrenia Neuron 52 2006 139 153
8. F.S. Menniti Allosteric modulation for the treatment of schizophrenia: targeting glutamatergic networks Curr. Top. Med. Chem. 13 2013 26 54
9. C.W. Lindsley Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr. Top. Med. Chem. 8 2006 771 784
10. J.R. Field Targeting glutamate synapses in schizophrenia Trends Mol. Med. 17 2011 689 698
11. J.T. Kantrowitz, and D.C. Javitt N-Methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull. 83 2010 108 121
12. R. Jin Mechanism of positive allosteric modulators acting on AMPA receptors J. Neurosci. 25 2005 9027 9036
13. P.J. Conn Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
14. P.J. Conn Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 2009 25 31
15. B.J. Melancon Allosteric modulation of 7 transmembrane spanning receptors: theory, practice and opportunities for CNS drug discovery J. Med. Chem. 55 2012 1445 1464
16. A.I. Levey Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain Life Sci. 52 1993 441 448
17. P. Abrams Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder Br. J. Pharmacol. 148 2006 565 578
18. L.A. Volpicelli, and A.I. Levey Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus Prog. Brain Res. 145 2004 59 66
19. M.W. Salter Src kinases: a hub for NMDA receptor regulation Nat. Rev. Neurosci. 5 2004 317 328
20. C.J. Langmead Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117 2008 232 243
21. J.M. Gold Cognitive deficits as treatment targets in schizophrenia Schizophr. Res. 72 2004 21 28
22. M.F. Green Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26 2000 119 136
23. M.F. Green Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr. Res. 72 2004 41 51
24. H. Salh-Uddin Altered M1 muscarinic acetylcholine receptor (CHRM1)-Gα(q/11) coupling in a schizophrenia endotype Neuropsychopharmacology 34 2009 2156 2166
25. J.W. Olney NMDA receptor hypofunction model of schizophrenia J. Psychiat. Res. 33 1999 523 533
26. A.K. Malhotra Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150
27. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
28. G.E. Duncan Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine Brain Res. 843 1999 171 183
29. P. Chue Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1) Curr. Pharm. Des. 19 2013 1311 1320
30. T. Lipina Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia Psychopharmacology 179 2005 54 67
31. M.J. Marino Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells PNAS 95 1998 11465 11470
32. C. Sur N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity PNAS 100 2003 13674 13679
33. A.D. Miller, and C.D. Blaha Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat Eur. J. Neurosci. 21 2005 1837 1846
34. C.K. Jones Pharmacologic interactions between the muscarinic cholinergic and dopaminigeric systems in the modulation of prepulse inhibition in rats J. Pharmacol. Exp. Ther. 312 2005 1055 1063
35. N.R. Mirza Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists CNS Drug Rev. 9 2003 159 186
36. 4 preferring agonist xanomeline reverses amphetamine-, MK-801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia Int. J. Neuropsychopharmacol. 14 2011 1233 1246
37. N.C. Bodick Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease Arch. Neurol. 54 1997 465 473
38. A. Shekhar Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia Am. J. Psychiatry 165 2008 1033 1039
39. J. Lieberman Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry Am. J. Psychiatry 165 2008 931 936
40. K.W. Perry The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex Biol. Psychiatry 49 2001 716 725
41. H.E. Shannon Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice Schizophr. Res. 42 2000 249 259
42. M. Wienrich Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease Drug Dev. Res. 56 2002 321 334
43. J.W. Clader, and Y. Wang Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease Curr. Pharm. Des. 11 2005 3353 3361
44. H. Fillit Health care utilization and costs of Alzheimer's disease: the role of comorbid conditions, disease stage, and pharmacotherapy Fam. Med. 34 2002 528 535
45. Z.S. Khachaturian Diagnosis of Alzheimer's disease Arch. Neurol. 42 1985 1097 1105
46. K.A. Welsh The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery Neurology 44 1994 609 614
47. A.A. Davis Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo J. Neurosci. 30 2010 4190 4196
48. S. Jiang M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation Neurosci. Lett. 515 2012 125 130
49. T.M. Bridges Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I. Exploration of alternative benzyl and privileged structure moieties Bioorg. Med. Chem. Lett. 18 2008 5439 5442
50. J. Nunan, and D.H. Small Regulation of APP cleavage by α-, β- and γ-secretases FEBS Lett. 483 2000 6 10
51. J.K. Shirey A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci. 29 2009 14271 14286
52. 1 positive allosteric modulator ML169 ACS Chem. Neurosci. 3 2012 884 895
53. Lindsley, C. et al. (2008) Merck & Co., Inc. Benzyl-substituted quinolone M1 receptor positive allosteric modulators. WO Patent 2,008,002,621
54. L. Ma Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation PNAS 106 2009 15950 15955
55. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20 2010 531 536
56. J.M. Zhou Early discrimination reversal learning impariment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice Neurobiol. Aging 28 2007 1248 1257
57. J.M. Zhou An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice Curr. Alzheimer Res. 5 2008 385 391
58. S. Lazareno Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies Mol. Pharmacol. 53 1998 573 589
59. 1 muscarinic receptor Mol. Pharmacol. 61 2002 1297 1302
60. 1-preferring receptor agonists Eur. J. Pharmacol. 605 2009 53 56
61. 1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model Neuropharmacology 58 2010 365 373
62. C. Langmead Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 154 2008 1104 1115
63. C.K. Jones Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28 2008 10422 10433
64. C. Jones TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antipsychotic-like effects in vivo Neuropsychopharmacology 31 2006 S116 S117
65. E.P. Lebois Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system ACS Chem. Neurosci. 1 2010 104 121
66. N.R. Miller Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II. Amides, sulfonamides and ureas - the effect of capping the distal basic piperidine nitrogen Bioorg. Med. Chem. Lett. 18 2008 5443 5447
67. 1 allosteric agonism and result in pan-mAChR orthosteric antagonism Bioorg. Med. Chem. Lett. 23 2013 223 227
68. A.G. Sams Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo [1,4] oxazin-4-yl) propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential J. Med. Chem. 53 2010 6386 6397
69. B. Budzik 2′ biaryl amides as novel and subtype selective M1 agonists. Part I. Identification, synthesis, and initial SAR Bioorg. Med. Chem. Lett. 20 2010 3540 3544
70. B. Budzik 2′ biaryl amides as novel and subtype selective M1 agonists. Part II. Further optimization and profiling Bioorg. Med. Chem. Lett. 20 2010 3545 3549
71. 1 agonists Bioorg. Med. Chem. Lett. 20 2010 5434 5438
72. B. Budzik Novel N-substituted benzimidazolones as potent, selective, CNS-penetrant, and orally active M1 mAChR agonists ACS Med. Chem. Lett. 1 2010 244 248
73. 11C GSK1034702 for clinical use on an Eckert & Ziegler Modular Lab system Appl. Radiat. Isotopes 69 2011 1390 1394
74. P.J. Nathan The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction Int. J. Neuropsychopharmacol. 16 2013 721 731
75. G.J. Digby Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol. BioSyst. 6 2010 1345 1354
76. D. Dencker Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse, and Parkinson's disease ACS Chem. Neurosci. 3 2011 80 89
77. E.P. Lebois Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071 Bioorg. Med. Chem. Lett. 21 2011 6451 6455
78. G.J. Digby Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models J. Neurosci. 32 2012 8532 8544
79. B.J. Melancon Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor Bioorg. Med. Chem. Lett. 22 2012 3467 3472
80. 1 agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode ACS Chem. Neurosci. 3 2012 1025 1036
81. A.A. Davis Differential effects of allosteric M1 muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation ACS Chem. Neurosci. 1 2010 542 551
82. R.L. Thomas Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation J. Pharmacol. Exp. Ther. 331 2009 1086 1095
83. S. Lin Expression of muscarinic receptor subtypes in rat gastric smooth muscle Dig. Dis. Sci. 42 1997 907 914
84. T.M. Bridges, and C.W. Lindsley G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 3 2008 530 541
85. S.D. Kuduk Novel M1 allosteric ligands: a patent review Expert Opin. Ther. Pat. 22 2012 1385 1398
86. 1 allosteric modulators ACS Med. Chem. Lett. 1 2010 263 267
87. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20 2010 1710 1715
88. 1 positive allosteric modulators with reduced plasma protein binding Bioorg. Med. Chem. Lett. 20 2010 2533 2537
89. 1 positive allosteric modulators ACS Med. Chem. Lett. 3 2012 1070 1074
90. J.M. Uslaner The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive performance in rat, cynomolgus macaque and rhesus macaque Psychopharmacology 225 2013 21 30
91. 1 positive allosteric modulator (PAM): the development of ML169, an MLPCN Probe Bioorg. Med. Chem. Lett. 21 2011 2697 2701
92. 1 PAM Bioorg. Med. Chem. Lett. 20 2010 1972 1975
93. 1 PAM ML137: the continued optimization of an MLPCN probe Bioorg. Med. Chem. Lett. 23 2013 1860 1864
94. 1 PAM ML137: the continued optimization of an MLPCN probe molecule Bioorg. Med. Chem. Lett. 23 2013 412 416